Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national nonprofit ...

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...

VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX ... Although there is currently no cure for glaucoma, early intervention – including prescription eye drops – can help slow the disease’s ...

Eye Drops for Red Eyes: LUMIFY significantly reduces redness to help reveal your eyes' natural radiance. From the eye care experts at Bausch and Lomb, LUMIFY works in 1 minute and lasts up to 8 ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

lifestyle changes impacting eye health, and increased affordability of healthcare services in emerging markets. The key players in the global ophthalmic lasers market include Alcon, Bausch + Lomb ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire ...

VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the ...

Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine ...